World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
79
Citations
24943
World Ranking
1674
National Ranking
825

Medicine

D-Index
79
Citations
24944
World Ranking
17482
National Ranking
8750

Catherine M. Bollard publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Catherine M. Bollard sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 629 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Catherine M. Bollard D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Catherine M. Bollard sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 79 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Catherine M. Bollard is affiliated with George Washington University in the United States. Their research spans multiple dimensions within medicine, with a significant focus on immunology and oncology. The scientist has primarily contributed to oncology, immunology, epidemiology, genetics, and infectious diseases across numerous publications.

The main areas of study include:

  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Immune cell function and interaction
  • Cytomegalovirus and herpesvirus research
  • Lymphoma diagnosis and treatment
  • Virus-based gene therapy research
  • HIV research and treatment

Catherine M. Bollard has published in several notable scientific journals and venues. The most frequent publication venues are:

  • Blood
  • Blood Advances
  • Cytotherapy
  • Transplantation and Cellular Therapy
  • Neuro-Oncology

The scientist's recent papers illustrate the scope and topics of their research:

  • "Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children", 2020, New England Journal of Medicine
  • "SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein", 2020, Blood
  • "Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma", 2022, Journal of Clinical Oncology
  • "BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo", 2020, Journal of Clinical Investigation
  • "Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.", 2020, PubMed

The scientist frequently collaborates with colleagues, including:

  • Patrick J. Hanley
  • Michael D. Keller
  • Carolina Colli Cruz
  • Haili Lang
  • Christopher A. Lazarski

The breadth of publication topics and consistent contributions to multiple fields highlight varied areas of study. Among them, immunotherapy and immune response mechanisms, especially in relation to cancer and viral infections, stand out within their research portfolio.

Best Publications

  • CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

    Barbara Savoldo;Carlos Almeida Ramos;Carlos Almeida Ramos;Enli Liu;Martha P. Mims

  • Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

    Helen E. Heslop;Karen S. Slobod;Martin A. Pule;Gregory A. Hale

  • Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

    Ann M. Leen;G. Doug Myers;Uluhan Sili;M. Helen Huls

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

    Ann M. Leen;Catherine M. Bollard;Adam M. Mendizabal;Elizabeth J. Shpall

  • Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

    Conrad Russell Y. Cruz;Kenneth P. Micklethwaite;Barbara Savoldo;Carlos A. Ramos

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

    Catherine M. Bollard;Catherine M. Bollard;Stephen Gottschalk;Stephen Gottschalk;Vicky Torrano;Vicky Torrano;Oumar Diouf;Oumar Diouf

  • Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin's disease

    Catherine M. Bollard;Catherine M. Bollard;Laura Aguilar;Karin C. Straathof;Benedikt Gahn

  • Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

    Ann M. Leen;Anne Christin;Gary D. Myers;Hao Liu

  • Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

    Karin C M Straathof;Catherine M. Bollard;Catherine M. Bollard;Catherine M. Bollard;Uday R Popat;M. Helen Huls;M. Helen Huls;M. Helen Huls

  • Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

    Carlos A. Ramos;Brandon Ballard;Huimin Zhang;Olga Dakhova

  • Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States

    Jeffrey I. Cohen;Elaine S. Jaffe;Janet K. Dale;Stefania Pittaluga

  • International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

    A Younes;P Hilden;B Coiffier;A Hagenbeek

  • Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

    Catherine M. Bollard;Catherine M. Bollard;Claudia Rössig;Claudia Rössig;M. Julia Calonge;M. Julia Calonge;M. Helen Huls;M. Helen Huls

  • Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

    Catherine M. Bollard;Stephen Gottschalk;Ann M. Leen;Heidi Weiss

  • Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

    Patrick J. Hanley;Conrad Russell Young Cruz;Barbara Savoldo;Ann M. Leen

  • T-cell therapy in the treatment of post-transplant lymphoproliferative disease

    Catherine M. Bollard;Cliona M. Rooney;Helen E. Heslop

  • Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

    Véronique Minard-Colin;Anne Aupérin;Marta Pillon;G.A. Amos Burke

  • Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory t cells without diminishing antiviral and antileukemic activity

    Alana A. Kennedy-Nasser;Stephanie Ku;Paul Castillo-Caro;Yasmin Hazrat

  • Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

    Chrystal U. Louis;Karin Straathof;Karin Straathof;Catherine M. Bollard;Catherine M. Bollard;Sravya Ennamuri;Sravya Ennamuri

  • Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

    Claudia Rossig;Catherine M. Bollard;Jed G. Nuchtern;Cliona M. Rooney

Frequent Co-Authors

Helen E. Heslop
Helen E. Heslop Baylor College of Medicine
Cliona M. Rooney
Cliona M. Rooney Baylor College of Medicine
Malcolm K. Brenner
Malcolm K. Brenner Baylor College of Medicine
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Adrian P. Gee
Adrian P. Gee Baylor College of Medicine
Ann M. Leen
Ann M. Leen Baylor College of Medicine
Stephen Gottschalk
Stephen Gottschalk St. Jude Children's Research Hospital
Barbara Savoldo
Barbara Savoldo University of North Carolina at Chapel Hill
Gianpietro Dotti
Gianpietro Dotti University of North Carolina at Chapel Hill
Hao Liu
Hao Liu Indiana University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various advanced healthcare careers, particularly in nursing and clinical research. Many professionals are now opting for online degrees to enhance their qualifications while balancing work and life commitments.

For nurses aiming to specialize further, exploring best online BSN programs for non nurses provides a solid foundation for entering immunology-related fields. These programs cater to those without a prior nursing background and facilitate entry into healthcare roles focused on immune system health.

Registered nurses can accelerate their career growth through accelerated RN to NP programs. These pathways are ideal for those seeking nurse practitioner roles with advanced clinical expertise in immunological disorders and patient care.

Certification is essential when transitioning into specialized roles, such as becoming an acute care nurse practitioner. Guidance on obtaining the acute care nurse practitioner certification is invaluable for those focusing on acute immunological conditions and complex patient management.

Lastly, understanding the financial landscape is crucial. The DNP salary transparency resource helps prospective students and professionals gauge potential earnings across different states, informing decisions about education investments and career planning in the immunology nursing sector.

Best Scientists Citing Catherine M. Bollard

Trending Scientists

Recently Published Articles